<SEC-DOCUMENT>0001193125-22-244962.txt : 20220915
<SEC-HEADER>0001193125-22-244962.hdr.sgml : 20220915
<ACCEPTANCE-DATETIME>20220914202052
ACCESSION NUMBER:		0001193125-22-244962
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220914
FILED AS OF DATE:		20220915
DATE AS OF CHANGE:		20220914

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		221244284

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d376714d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated September 14, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d376714dex991.htm">Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod
 Alpha </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: September 14, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d376714dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g376714g01w84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Clinical Development Update for its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class</FONT></FONT>
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">LAG-3</FONT> Antigen Presenting Cell Activator Candidate Eftilagimod Alpha </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Encouraging Phase II data supports broad therapeutic potential of eftilagimod alpha in <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head&nbsp;&amp; neck squamous cell cancer (HNSCC) and metastatic breast cancer (MBC) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Planning and regulatory interactions ongoing with a focus now prioritising 1<SUP
STYLE="font-size:75%; vertical-align:top">st</SUP> line (1L) NSCLC </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New and important clinical data in 1L NSCLC expected in Q4 2022 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continued expansion of efti in additional indications and combinations planned </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strong balance sheet provides cash runway into early 2024 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 14</B><B></B><B>&nbsp;September 2022 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a biotechnology company developing novel <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">LAG-3-related</FONT></FONT> immunotherapy treatments for cancer and autoimmune disease, provides a clinical development update
for its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">LAG-3</FONT> antigen-presenting cell (APC) activator product candidate, eftilagimod alpha (&#147;efti&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CEO Marc Voigt said:</B> &#147;Efti is an innovative
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">LAG-3-based</FONT></FONT> clinical candidate with broad therapeutic potential supported by encouraging activity and well-tolerated safety in multiple Phase II trials in solid tumor
indications including NSCLC, HNSCC and MBC. Recent data from <FONT STYLE="white-space:nowrap">TACTI-002,</FONT> a frontline, <FONT STYLE="white-space:nowrap">PD-L1</FONT> <FONT STYLE="white-space:nowrap">all-comer</FONT> trial in NSCLC, demonstrated
that efti in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy delivered a clinical benefit in patients across all levels of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression,
including patients with negative <FONT STYLE="white-space:nowrap">PD-L1.</FONT> Based on this compelling data, coupled with the large market opportunity and high unmet need for more durable and tolerable options, our late-stage clinical development
efforts will focus on frontline NSCLC in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy. We look forward to providing additional clinical data in 1L NSCLC later this year.
Regulatory interactions and late-stage planning to evaluate efti in MBC, another attractive opportunity for efti, will also continue.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.</B><B></B><B>&nbsp;Frederic Triebel, Immutep&#146;s CSO and CMO added</B>: &#147;Well-tolerated treatment options that can synergise with standards of
care to improve outcomes across the <FONT STYLE="white-space:nowrap">PD-L1</FONT> spectrum remain a high unmet need in NSCLC. We are particularly encouraged by the ability of efti to demonstrate benefit across all levels of <FONT
STYLE="white-space:nowrap">PD-L1</FONT> status, and particularly in patients with negative or low <FONT STYLE="white-space:nowrap">PD-L1</FONT> levels who typically respond poorly to checkpoint treatment. This could be explained by the orthogonal
therapeutic approach in <FONT STYLE="white-space:nowrap">TACTI-002</FONT> where efti first activates innate immunity via monocytes, dendritic cells, and NK cells and leads to the activation of more T cells, enhancing the effect of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy. Data from <FONT STYLE="white-space:nowrap">TACTI-002</FONT> support the potential of this <FONT STYLE="white-space:nowrap">IO-IO</FONT> combination to not
only offer a chemotherapy-free option for a broad range of NSCLC patients but also expand the potential market opportunities of current immune checkpoint approaches. We look forward to maximising the full treatment potential of efti in patients with
advanced solid tumors.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g376714g01w84.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Late-Stage Efti Clinical Development Updates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pathway in Lung Cancer <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(anti-PD-1</FONT></FONT> combination with or without chemo)
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is prioritising 1L NSCLC in terms of late-stage clinical strategy, based on compelling data, coupled with the large market opportunity and
continued high unmet need for more durable and tolerable options. In combination with top selling drug in oncology, Keytruda<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, efti has been delivering strong results, especially in patients
known to respond less than <FONT STYLE="white-space:nowrap">optimally/sub-optimally</FONT> to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> treatment (e.g. patients with negative or low <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression levels). Immutep&#146;s next steps in NSCLC will be shaped by the maturing <FONT STYLE="white-space:nowrap">TACTI-002</FONT> data, with additional data expected in Q4 2022 and feedback from
regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Initial results from Immutep&#146;s ongoing <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> trial evaluating efti in
combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy and chemotherapy are also expected in Q4 2022. These results may help to further inform the design of our late-stage trial in 1L
NSCLC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pathway in Head and Neck Cancer <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(anti-PD-1</FONT></FONT> combination)
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, 47/154 patients (approximately 30%) have been recruited into Immutep&#146;s ongoing randomised Phase IIb
<FONT STYLE="white-space:nowrap">TACTI-003</FONT> trial in 1L HNSCC. Recruitment is accelerating as further sites have been activated. The trial is being conducted in collaboration with Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA (known as
&#147;MSD&#148; outside the United States and Canada). Efti in 1L HNSCC has Fast Track designation by the FDA, which provides Immutep with access to more frequent meetings and communications with the FDA, and potentially enables Rolling Review of a
Biologic License Application. In addition, Fast Track designation may provide Accelerated Approval and Priority Review if relevant criteria are met, for efti in HNSCC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pathway in Breast Cancer (chemo combination) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep
will continue with preparations for future clinical development in MBC, including engagement with the regulators, Contract Research Organisations and other stakeholders, each of which are progressing. Efti has shown encouraging clinical data in
combination with chemotherapy in this indication, including statistically significant improvements in overall survival (OS) across several <FONT STYLE="white-space:nowrap">pre-defined</FONT> subgroups. As such, MBC remains an attractive opportunity
for efti. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ultimately, Immutep will aim to obtain marketing authorisation of efti in multiple indications, positioning the Company, or a potential
partner, strongly to fully exploit the compelling potential of this unique clinical candidate to help a wide range of cancer patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Upcoming
Clinical Data Updates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep plans to provide further clinical trial updates in Q4 2022, as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">more data from <FONT STYLE="white-space:nowrap">TACTI-002</FONT> in 1L NSCLC, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">first results from the <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> study, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an update from the <FONT STYLE="white-space:nowrap">TACTI-003</FONT> study. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Clinical Trials </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to Immutep&#146;s
current development program, the company is also engaged in discussions with a number of external parties to test efti in new settings. The expansion of clinical settings will help to further explore the potential of efti and enhance its value. A
first example is the recently announced new Phase II </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g376714g01w84.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investigator-initiated study in soft tissue sarcoma with efti in combination with pembrolizumab and radiotherapy in the neoadjuvant setting. We hope to have further updates regarding these
potential new settings in the coming weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Including the planned program expansion, Immutep remains well-funded with ~$80&nbsp;million in cash as of
30&nbsp;June 2022, providing a cash runway into early CY2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology company that is a leader in the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related
immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product
candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator being explored in cancer. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products, including antibodies for immune response modulation, are being developed by Immutep&#146;s
large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim McCarthy, LifeSci Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (917) 679 9282;&nbsp;<U>tim@lifesciadvisors.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the Board of Immutep Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 George Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g376714g01w84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g376714g01w84.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@!"<4 <KJ?C..VF:&SB68KP78X7/MZUC*K;8XZF*479%2V\8ZBT
MT8DT]9%D/RB,,"WTZYI*H^Q"Q,VUH=98W\-_;^;$2"#M9&&&0^A%;)W.V,E+
M8M4R@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#(\2W+VNA7+QG#$!01VR0*B;LC&L^6#.1TFPLM<N(;<1-;&&/,A
M4Y\SD>O2L8I2..G&%5V-G5M.AT"VCU"P#"2'Y%#L64;LY./6M)1Y5=&]2/LE
MSQ,OPSJ5Q+XES(^?M6[>!TR!G^E13DVS*A-NHSOQQ70>@+0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % "$D#@9
M- '"^%]9\17OB&6#4(G%N Q<-%M$9'3!H [N@ H * "@ H * "@ H * "@ H
M * "@ H Y[5_&6FZ+=M:7"S/.H!*HGK[DT ;EO,+BWBF4$+(H8 ]1D9H EH
M* "@ H * "@"CJUC_:.F3VN<%U^4^A'(_44I*ZL14CS1:. TV.73;N>>2X6V
MGM1_JGZR>WTKF7NGG4X^S;;Z#KWQ+?7^Q9UB,*D$Q!?E;Z]Z.=O04J[EN:WA
M'29&N3J<J>7'SY2XZY[_ $[5<(]3?#TW?G9VHK<[@H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MU_)%HF@W$MO$J1VT3%$ X'' _.@#RGPXNG7FMO<:Y<J(@#(?,)_>/GO_ #H
M['59?!U]IDL"36<4NT^6\:;2K=N@H Q/AO>O%K<UIN/E31%L?[0(P?R)H I>
M//\ D;;C_<3_ -!% 'I(\.:,]NJ'2[7&.T0!_.@#S+Q/I?\ PC/B%#9.R1D"
M:$YY7GI^8H ]9TR[%]I=K=@8\Z-7QZ9% %J@ H * "@ H * "@ H * "@ H
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M;/>-"/R_^M0!ZCI$BRZ/9.ARI@0@_P# 10!7\1P/<^'-0BC&7,+$ =R.?Z4
M>5>%]+L-8U1K.^GDAW)F(H0,GTY'I0!VW_"M-*_Y^[O_ +Z7_"@"_HW@NPT3
M4%O+>>=Y%4KAR,<_04 <-X]X\6W'^XG_ *"* /6XS^Z0CT% 'EOQ%O(KC7XH
M8V#&"(*V.S$DX_+% 'HF@0/:^'["&08=(%##T.* -&@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * &R#
M*$#TH$]CCO#_ (>U#3M7CN+B-!&JL"0X/45C&#3N<=*C*$[LO>*='O-5^R_9
M45O+W;LMCKC_  IU(N6QIB*;GL:FB6LMEI%O;3 "1 00#GN:N*LC6G%QBDS
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M,?F* 'BYA:..02 I(0%/J: &-?6RS&$N2ZD*0%)P< _R(H )=0M8)3'+*$8
M$Y!PN>F3T% $D]Q%:PM-,ZQQKU9C@"@ GN(K:,/*VU2<# SD_04 1I?VKQ^8
MLRE P0GT8] ?0\B@"998WD>-6!=,;AZ9Z4 >2>/?^1NN/]Q/_010!ZY'_JE^
M@H =0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * # H ,4 )@4
M+0 8 [4 &* # Z4 &* "@ Q0 8H * #% !0 8% !@>E "8'I0 N,4 &!0 4
M% !B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* $R* %R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B
M@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R*
M#(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,
MB@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R*
M #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H
M,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R
M* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* #(H ,B@ R* /*_P"T-8_Y^KS_
M +Z:N5N1Y/-4%_M#6/\ GZN_^^VI<TA<U0/[0UC_ )^KO_OMJ.:0<U0/[0UC
M_GZN_P#OMJ.:0<U0/[0UC_GZN_\ OMJ.:0<U0/[0UC_GZN_^^VHYI!S5 _M#
M6/\ GZN_^^VHYI!S5 _M#6/^?J[_ .^VHYI!S5 _M#6/^?J[_P"^VHYI!S5
M_M#6/^?J[_[[:CFD'-4#^T-8_P"?J[_[[:CFD'-4#^T-8_Y^KO\ [[:CFD'-
M4#^T-8_Y^KO_ +[:CFD'-4#^T-8_Y^KO_OMJ.:0<U0/[0UC_ )^KO_OMJ.:0
M<U0/[0UC_GZN_P#OMJ.:0<U0/[0UC_GZN_\ OMJ.:0<U0/[0UC_GZN_^^VHY
MI!S5 _M#6/\ GZN_^^VHYI!S5 _M#6/^?J[_ .^VHYI!S5 _M#6/^?J[_P"^
MVHYI!S5 _M#6/^?J[_[[:CFD'-4#^T-8_P"?J[_[[:CFD'-4#^T-8_Y^KO\
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M.:0<U0/[0UC_ )^KO_OMJ.:0<U0/[0UC_GZN_P#OMJ.:0<U0/[0UC_GZN_\
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M_P#OMJ.:0<U0/[0UC_GZN_\ OMJ.:0<U0/[0UC_GZN_^^VHYI!S5 _M#6/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
7"@ H * "@ H * "@ H * "@ Q28C_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
